Starpharma Holdings Limited · ASX:SPL
Starpharma — Shareholder Meeting (November 2010)
25 slides from Starpharma's shareholder meeting presentation, Nov 11, 2010
Slide 1: AGM Chairman's and CEO's presentations
AGM A - Chairman’s s and CE EO’s pres sentation ns For personal use only Melbou urne; 11 Noovember 20 010: Attach hed is the C Chairman’s address a tog gether with the t CEO’s presentation to the Annual Generral Meeting of Starpharrma Holding gs Limited (ASX:SPL, OTCQX X:SPHRY), to be held at 4.00pm
Slide 2: Chairman's Address
Chairman’s Address Annual General Meeting For personal use only of Starpharma Holdings Limited, 11 November 2010 It is my pleasure to welcome you to the 2010 annual general meeting of Starpharma Holdings Limited. I enjoy this now regular opportunity to brief shareholders on the year’s highlights as
Slide 3: Chairman's Address (continued)
shown to significantly reduce life-threatening toxicities of cancer drugs and to extend the duration of action of a variety of molecules including insulin and small molecule drugs. Starpharma has also identified industrial, cosmetic and water treatment applications of dendrimers that have yet to be
Slide 4: CEO Presentation
For personal use only Starpharma Holdings Limited ASX:SPL OTCQX:SPHRY Annual General Meeting CEO Presentation 11 November, 2010 Dr Jackie Fairley CEO
Slide 5: Forward-looking statements
For personal use only This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targe
Slide 6: Starpharma Holdings Limited - Investment Summary
For personal use only Starpharma Holdings Limited - ASX:SPL Investment Summary Attractive commercial partnership for VivaGel® coated condom 9 November 2010 – VivaGel® Condom Coating licensed to Reckitt Benckiser (RB) ASX Code SPL – Sales/royalty revenues expected to commence in CY11 Share Price SPL
Slide 7: Dendrimers – A Versatile Platform Technology
For personal use only Dendrimers – A Versatile “Platform” Technology “SPL is one of the few companies in Australian biotechnology sector that has what we consider to be a true technology platform which can be used for a wide range of healthcare and industrial applications.” Shaw Stockbroking, 9 Dec
Slide 8: Highlights for 2009/2010
For personal use only Highlights for 2009/2010 Starpharma and Lilly sign new drug delivery collaboration; Extended in Sept 2010 VivaGel ® coated condom – good progress; Durex ‘s market position strengthened Reckitt Benckiser acquires Starpharma’s partner SSL; Durex designated a RB “Powerbrand”
Slide 9: Share price performance relative to peers
For personal use only Share price performance relative to peers and domestic healthcare companies Peer companies’⁽1⁾ share price performance since 1 January 2009 544% 300% 254% 244% 250% 200% 187% 175% 150% 134% 100% 51% 50% 31% 33% 22% 15% 21% 8% 2% 9% 0% (25%) (25%) (50%) (37%) (42%) (59%) (58%) (
Slide 10: Financial Summary
For personal use only Financial Summary FY 2008 FY 2009 FY 2010 $M $M $M Royalty, customer & license revenue 1.4 2.0 1.4 Grant, interest and other income 8.5 7.8 4.5 Total revenue and income 9.9 9.8 5.9 Net loss after tax (7.5) (4.1) (6.4) Net cash outflow before new capital (Cash Burn) (6.1) (2.9)
Slide 11: Starpharma's Commercial Partnerships
For personal use only Starpharma’s Commercial Partnerships Starpharma’s aim is to partner with market-leading companies VivaGel® Co-development and licence for Condom Coating (excl. Japan) Dendrimers for Drug Delivery Lilly, Elanco, Stiefel (GSK); Drug delivery collaborations Multibillion dollar US
Slide 12: Pipeline: Dendrimers – A Versatile Platform Technology
For personal use only Pipeline: Dendrimers – A Versatile “Platform” Technology Early or lead Development Marketed VivaGel® Condom Coating Gel : HIV/HSV preventative Gel : BV treatment drug delivery Undisclosed diagnostics Undisclosed laboratory reagents agrochemical Undisclosed 9 Cosmetic/ industria
Slide 13: VivaGel - Anti-viral Condom Coating and Microbicide Gel
For personal use only VivaGel® - 2 Products: Anti-viral Condom Coating and Microbicide Gel VivaGel®-Coated Condom VivaGel® Vi va Gel ® Condom coated with patented antiviral Topical Microbicide Gel - inactivates viral STIs Product - for the prevention of (HIV, Herpes, HPV) viral STIs (HIV, Herpes, HP
Slide 14: VivaGel-Coated Condom
For personal use only VivaGel®-Coated Condom Licensed to Reckitt Benckiser, owners of Durex® the leading global condom brand Starpharma Income Scenarios 35 Starpharma annual income 30 25 20 USD(M) 15 Vi vaG 10 el ® 5 0 low med high Fraction of SSL’s range • Anti-viral Condom Coating coated with Viva
Slide 15: VivaGel-Coated Condom: Reckitt Benckiser and SSL/Durex takeover
For personal use only VivaGel®-Coated Condom Reckitt Benckiser and commentary of its takeover of SSL/Durex Market commentary on takeover Reckitt Benckiser (LSE:RB) is one of the world’s “Reckitt Benckiser promises 'heavy' support for largest marketers of branded household, health and the brands foll
Slide 16: VivaGel - Anti-viral Condom Coating and Microbicide Gel
For personal use only VivaGel® - Anti-viral Condom Coating and Microbicide Gel Product Indication Regulatory Market Path Potential USD STI (HIV/HSV2) VivaGel® $3-6Bi 1 Prevention Drug Standalone Gel Phase 2 BV treatment & VivaGel® prevention of Drug $300-350M 1 Standalone Gel recurrence Phase 2 Drug
Slide 17: Completed VivaGel Clinical Trials
For personal use only Completed VivaGel® Clinical Trials Study N= Site(s) Status HIV and HSV-2 Inhibition In Vitro Following Vaginal Administration Objectives: Safety, tolerability and PK of VivaGel® (mean ± SEM) Adelaide, Schedule: Administered vaginally, once 37 Complete Australia daily for 7 days
Slide 18: VivaGel - Bacterial Vaginosis: An Attractive Commercial Opportunity
For personal use only VivaGel® - Bacterial Vaginosis (BV) –Treatment and Prevention of Recurrence An Attractive Commercial Opportunity The most common vaginal infection worldwide 21 million women infected with BV in US, (up to 51% in certain demographics) Causes unpleasant discharge, increased
Slide 19: VivaGel - Recurrent BV: changing the paradigm
For personal use only VivaGel® - Bacterial Vaginosis (BV) Recurrent BV - changing the paradigm with VivaGel ® VivaGel® as a better/alternative VivaGel® as an ongoing therapy for acute treatment for BV suppression/prevention of recurrent BV 16
Slide 20: VivaGel BV Development Plan and Progress
For personal use only VivaGel® - Bacterial Vaginosis (BV) Development Plan and Progress FDA and MHRA scientific advice obtained on clinical development program US IND accepted July 2010 – SPL7013 Gel for bacterial vaginosis Phase II Dose Ranging Treatment Study underway: – SPL7013 Gel once dai
Slide 21: Dendrimers for Drug Delivery
For personal use only Dendrimers for Drug Delivery Advantages include – reduced toxicity, less frequent dosing and new patents Capabilities of Starpharma’s Technology include: Attached Drug Molecule Product lifecycle management ( extend patent life) Improved efficacy of drugs Extension of drug
Slide 22: Drug Delivery applications have the potential to create significant value
For personal use only Drug Delivery applications have the potential to create significant value Examples of companies which have created value through drug delivery Paclitaxel (Taxol®) & water Therapeutic Company Valuation Value driver Focus Abraxane : global VivaGel® sales >USD 300M. Abraxis (a nan
Slide 23: Value Drivers for Starpharma
For personal use only Value Drivers for Starpharma VivaGel® - Coated Condom to market Complete co-development with Reckitt and support product launch/roll-out Sign marketing partner for Japan (the world’s second largest condom market) Advance VivaGel® clinical development Complete Phase 2 Bact
Slide 24: Broker Analysis and Commentary
For personal use only Broker Analysis and Commentary Broker valuations (2), (3) Broker / Newsletter commentary Average Share Price $0.50 Average broker valuation $1.26 “...we see the pullback in the stock as an enticing entry point into a Company with multiple at initiation shots on goal with its te
Slide 25: Starpharma Holdings Limited contact
For personal use only Starpharma Holdings Limited ASX:SPL OTCQX:SPHRY Dr Jackie Fairley CEO +613 85322704 Further information: www.starpharma.com info@starpharma.com 22
Starpharma Holdings — Shareholder Meeting (November 2010) on 6ix